title: Aberrant expression and localization of hnRNP-A2/B1 is a common event in human gastric adenocarcinoma.
abstract: OBJECTIVE
  Nuclear-matrix proteins can be proteomic markers for cancer lesions. The present study aimed to determine the roles of heterogeneous nuclear ribonucleoproteins--A2 and B1 (hnRNP-A2/B1) in human gastric carcinogenesis.
  
  
  METHODS
  Human gastric cancer and non-cancerous tissues were collected for immunohistochemical analysis. Proteomics technique, Western blot, laser confocal microscope, and real-time quantitative reverse transcription-polymerase chain reaction were performed to determine the aberrant expression of nuclear-matrix proteins.
  
  
  RESULTS
  hnRNP-A2/B1 existed in the nuclear matrix of gastric cancer cells, and its expression was enhanced in human gastric cancer and decreased by hexamethylene bisacetamide. The colocalization of hnRNP-A2/B1 with c-myc, c-fos, p53, and Rb was translocated from the nucleolus to the cytoplasm during the differentiation of tumor cells.
  
  
  CONCLUSIONS
  hnRNP-A2/B1 affected tumor cell differentiation through interaction with oncogenes and tumor-suppressor genes, and it was overexpressed in human gastric cancer. We postulate that hnRNP-A2/B1 could serve as a biomarker for the diagnosis of human gastric cancer.
authors.affiliation: Key Laboratory of Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, Xiamen, China.
authors.forename: Guang-Jun
authors.initials: GJ
authors.lastname: Jing
authors.forename: Dong-Hui
authors.initials: DH
authors.lastname: Xu
authors.forename: Song-Lin
authors.initials: SL
authors.lastname: Shi
authors.forename: Qi-Fu
authors.initials: QF
authors.lastname: Li
authors.forename: San-Ying
authors.initials: SY
authors.lastname: Wang
authors.forename: Fu-Yun
authors.initials: FY
authors.lastname: Wu
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Kong
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D015153:Blotting, Western; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D002681:China; D003593:Cytoplasm / Q000378:metabolism; D034481:Heterogeneous-Nuclear Ribonucleoprotein Group A-B / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D018613:Microscopy, Confocal; D015530:Nuclear Matrix / Q000378:metabolism; D011379:Prognosis; D040901:Proteomics / Q000379:methods; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D000081:Acetamides; D014408:Biomarkers, Tumor; D034481:Heterogeneous-Nuclear Ribonucleoprotein Group A-B; C489427:MYC protein, human; D016760:Proto-Oncogene Proteins c-fos; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D016160:Retinoblastoma Protein; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C439768:hnRNP A2; C014026:hexamethylene bisacetamide